Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

The discovery of therapeutic monoclonal antibodies (mAbs) primarily focuses on their biological activity favoring the selection of highly potent drug candidates. These candidates, however, may have physical or chemical attributes that lead to unfavorable chemistry, manufacturing, and control (CMC) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Joschka, Mathias, Sven, Kube, Sebastian, Otte, Kerstin, Garidel, Patrick, Gamer, Martin, Blech, Michaela, Fischer, Simon, Karow-Zwick, Anne R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531517/
https://www.ncbi.nlm.nih.gov/pubmed/32658605
http://dx.doi.org/10.1080/19420862.2020.1787121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531517/
https://www.ncbi.nlm.nih.gov/pubmed/32658605
http://dx.doi.org/10.1080/19420862.2020.1787121

Ejemplares similares